Navigation Links
Champions Oncology Reports Full Year 2011 Financial Results
Date:7/15/2011

r POS were 53% and 65%, respectively.  The decrease in gross margin was attributable to the reduction in POS prices that the Company has instituted to increase affordability and market potential of the services being offered.

Costs of TOS for the fiscal year 2011 and 2010 were $1.5 million and $0.8 million, respectively, an increase of $0.7 million, or 93%.  For the fiscal year 2011 and 2010, gross margins for TOS was 56% and 53%, respectively.  

Research and DevelopmentResearch and development, or R&D, expenses for fiscal year 2011 and 2010 were $3.0 million and $2.6 million, respectively, an increase of $0.4 million, or 12%.  The increase in R&D expenses in 2011 was primarily due to the Company's increased spending on its technology platform and Tumorgraft testing on the company's in-licensed compounds.

General and AdministrativeGeneral and administrative, or G&A, expenses for the fiscal year 2011 and 2010 were $4.6 million and $2.8 million, respectively, an increase of $1.8 million, or 67%.  The increase was primarily due to the $2.3 million of non-cash stock-based compensation expense related to stock options issued to the Company's Chief Executive Officer and President.

Sales and MarketingSales and marketing expenses for the fiscal year 2011 and 2010 were $1.4 million and $0.5 million, respectively, and increase of $0.9 million or 173%.  The increase was primarily due to the hiring of additional sales employees and $0.3 million in new marketing efforts.

Other Income (Expense), NetOther income (expense), net for the fiscal year 2011 was $1.5 million, which primarily relates to grant income earned under the Qualifying Therapeutic Discovery Project program administered under Section 48D of the Internal Revenue Code based on the qualifying expenses incurred through the fiscal year ended April 30, 2011.

Cash and Cash EquivalentsThe Company's cash position on April 30,
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
2. Champions Biotechnology Changes Name to Champions Oncology
3. Champions Announces Technology Collaboration Utilizing Champions Tumorgraft™ Technology Platform for Oncology Drug Development
4. Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
5. Champions Biotechnology Reports Additions to its Management Team
6. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
7. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
8. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
9. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
10. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
11. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... -- Ryan & Maniskas, LLP that a class ... for the Northern District of California ... common stock of Avalanche Biotechnologies, Inc. ("Avalanche" or the "Company") ... 15, 2015, inclusive (the "Class Period"). Avalanche shareholders ... for appointment as a lead plaintiff of the Class.  If ...
(Date:7/24/2015)... Origin Agritech Limited (NASDAQ GS: SEED) ("Origin", or the "Company"), ... , today announced that the Company will report results ... 2015, before the market opens on Wednesday, August 5th, 2015. ... 5th, 2015, at 9:00 a.m. ET / 9:00 p.m. ... participate in the call, please dial the following numbers approximately ...
(Date:7/23/2015)... ... July 23, 2015 , ... The health and wellness of brain tumor ... of a brain tumor diagnosis. The American Brain Tumor Association presents interactive sessions that ... and Family Conference, July 24-25 in Chicago. , “We have understood for a ...
(Date:7/23/2015)... ... July 23, 2015 , ... The Pittcon 2016 Program ... S. Mosher Professor of Chemistry and Professor, by courtesy, of Applied Physics at Stanford ... Detection in Solids Led to Super-Resolution Nanoscopy in Cells and Beyond” , Dr. ...
Breaking Biology Technology:Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 2Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 3The 2014 Nobel Prize in Chemistry Recipient W. E. Moerner, to Deliver Wallace H. Coulter Lecture at Pittcon 2016 2The 2014 Nobel Prize in Chemistry Recipient W. E. Moerner, to Deliver Wallace H. Coulter Lecture at Pittcon 2016 3
... YORK, March 5 Bristol-Myers Squibb,Company (NYSE: ... of Directors,has elected Jean-Marc Huet senior vice president ... this role, Mr. Huet will be,responsible for directing ... the global financial operations of the organization and ...
... projects ONOM@TOPIC and SilOnIS shared ... the most innovative and sustainable project in ... European smartcard platform for,citizenship and mobile multimedia ... secure for users,while adding value for network ...
... March 4 On Wednesday, March 5, 2008,at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 ... CTIC),management team will host a conference call to discuss the company,s recent,transactions targeting cleaning ... ... ...
Cached Biology Technology:Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 2Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 3MEDEA+ Noblanc award highlights improvements in microelectronics 2MEDEA+ Noblanc award highlights improvements in microelectronics 3Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones 2
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. ... of human interface solutions, today announced a ... first fully hardware encapsulated fingerprint sensor and ... technology is literally off the grid, isolating ... matching within the fingerprint sensor to provide ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... people are biologically more susceptible to drug addiction than others, ... In the August 15, 2007 issue of the Journal of ... study that may help answer this question. ... had a particular receptor in the brain that is more ...
... August 15, 2007) A prominent problem in AIDS ... to concentrate and perform normal movements. Scientists at ... how HIV/AIDS disrupts the normal replication of stem cells ... forming. Drs. Stuart Lipton, Marcus Kaul, Shu-ichi Okamoto ...
... reported new insight into the pathology underlying a ... that is caused by alterations in the same ... tremor/ataxia syndrome (FXTAS) overwhelmingly affects males, usually in ... In contrast, fragile X syndrome manifests itself from ...
Cached Biology News:Nicotinic receptors may be important targets for treatment of multiple addictions 2AIDS interferes with stem cells in the brain 2AIDS interferes with stem cells in the brain 3Deep into the machinery of adult fragile X 2Deep into the machinery of adult fragile X 3
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... atoms at the 9, 10, 12, and 13 ... internal standard for the quantification of 9(S)-HODE by ... the lipoxygenation of linoleic acid in both plants ... plaques, as an esterified component of membrane phospholipids ...
... 9(S)-HODE-d4 contains 4 deuterium atoms at the ... intended for use as an internal standard for ... spectrometry. 9(S)-HODE is produced by the lipoxygenation of ... has been detected in atherosclerotic plaques, as an ...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: